LAGUNA HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF at the 2021 Heart Rhythm Society Annual Meeting. The late-breaking […]
Tag: Adagio Medical
Adagio Medical, Inc., reports pre-clinical effectiveness combining their existing ultra-low temperature cryoablation catheter with Pulsed Field Ablation (PFA) in a single Pulsed Field Cryoablation (PFCA) catheter
LAGUNA HILLS, Calif., Aug. 3, 2020 /PRNewswire/ — Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AFib) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced successful pre-clinical results demonstrating their existing cryoablation catheter is also capable of ablating the tissue through pulsed field ablation (PFA) delivered […]
Adagio Medical Announces US FDA Investigational Device Exemption Approval With Conditions To Conduct A Clinical Study For Treatment Of Persistent Atrial Fibrillation Using The Ultra-Low Temperature Cryoablation System
LAGUNA HILLS, Calif., Aug. 19, 2019 /PRNewswire/ — Adagio Medical, Inc. (Adagio), the developer of iCLAS™, the company’s ultra-low temperature intelligent continuous lesion ablation system, announced that it has received an Investigational Device Exemption approval with conditions from the US Food and Drug Administration (FDA) to conduct a non-randomized, single-arm clinical study for persistent atrial […]
Audio: Hakon Bergheim, COO of Adagio Medical speaks with CardiacVascularNews
Audio recording: Hakon Bergheim, COO of Adagio Medical speaks with CardiacVascularNews